Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus REXULTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus REXULTI.
LYBALVI vs REXULTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic